the foot. The Spearman correlation coefficient between the DECT urate volume and the number of joints with a positive DC sign was 0.15.

Conclusions: US and DECT do not provide the same assessment of tophus size. The correlation is improved when considering tophi localized in the feet. The number of joints with positive DC sign does not correlate to the volume of urate deposition in the soft tissues measured by DECT.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.4118

THU0403 URATE-LOWERING TREATMENT AND RISK OF INCIDENT UROLITHIASIS IN PEOPLE WITH GOUT: A NESTED CASE-CONTROL STUDY

C.-F. Kuo, J.-S. Chen. *Division of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Taoyuan, Taiwan, Province of China*

Background: A higher risk of urolithiasis has been reported in gout patients. However, whether urate-lowering treatments, including both xanthine oxidase inhibitors and uricosuric agents, are beneficial to reduce the risk of urolithiasis in gout patients has not been examined.

Objectives: To investigate the independent associations between urate-lowering treatment (ULT) and the risk of urolithiasis in incident gout patients.

Methods: We conducted a nested case-control study based on the Taiwan National Health Insurance Research Database (NHIRD), which was used to identify 473,858 newly diagnosis gout patients during the period from January 1, 2000 through December 31, 2004. All these patients were followed until December 31, 2013. We considered patients who first diagnose incident urolithiasis after the date of entry cohort (gout onset) as cases and the diagnostic date was defined as index date. Each case was matched up to five eligible controls whose follow-up period included the case's index date by sex, birth of year and gout diagnosis year. And the index date of case was assigned to the matched controls. Odds ratios (ORs) and 95% confidence interval (CI) of urolithiasis associated with cumulative defined daily dose (cDDD) of xanthine oxidase inhibitor and uricosuric agents were main outcome measures.

Results: Gout patients with incident urolithiasis (n=32,654) occurring after the initial diagnosis of gout aged 20–79 were age- and sex-matched 1:5 to 163,270 gout patients without urolithiasis. After adjusting for age, sex, urbanization status, income, occupation, and pertinent drugs and comorbidities, the OR of urolithiasis associated with use of ULT among gout patients were 1.04 (95% CI 1.00 to 1.07) for those with 28–90 cDDD, 0.95 (95% confidence interval 0.91–0.99) for 91–365 cDDD and 0.77 (95% confidence interval 0.73–0.82) for >365 cDDD, compared with those with a cDDD <28. The OR (95% CI) for urolithiasis associated with xanthine oxidase inhibitor use was 0.94 (0.89–0.99) for 28–90 cDDD, 0.90 (0.84–0.97) for 91–365 cDDD and 0.73 (0.63–0.83) for >365 cDDD. For uricosuric agents, the OR (95% CI) for urolithiasis among those with 28–91, 91–365 and <365 cDDD were 1.04 (1.01, 1.08), 0.94 (0.90–0.98) and 0.78 (0.73–0.84), respectively.

Conclusions: Higher ULT consumption was associated with a lower risk of urolithiasis. Xanthine oxidase inhibitors associated with reduced urolithiasis risk consistently across the range of consumption studied but for uricosuric agents inadequate cumulative dose results in a higher risk despite the risk reduced gradually with a higher cumulative dose.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.2913

THU0404 SELF-REPORTED SEVERITY OF GOUT IN A PRIMARY CARE SETTING AND ASSOCIATED FACTORS – RESULTS FROM A GOUT SURVEY IN PRIMARY CARE

A.J. Landgren, M. Dehlin, U. Bergsten, V. Sigurdardottir, P. Drivelegka, T. Zverkova Sandström, L. Jacobsson. *Department of Rheumatology and Inflammation Research, Institution of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden*

Background: Patients with gout are usually seen in primary care. There are numerous reports regarding severity of gout in cohort studies and patients seen in more specialized care, less is known about the spectrum of severity of the disease in primary care.

Objectives: To describe the pattern of self-reported disease severity of gout and predictors thereof in a primary care setting.

Methods: All patients above 18 with an ICD10-diagnosis of gout at a health care visit in primary care (Jan 2015 through Aug 2016) were identified from primary care within the Western Sweden Health Care Region (WSHCR). 941 patients were identified and included in the study. They were sent a questionnaire with questions regarding comorbidities, demographics, gout characteristics and Health Assessment questionnaire (HAQ) reflecting disability. Self-reported disease severity was assessed by a three-level Likert scale (mild, moderate, severe). Possibly associated factors were analyzed by bivariate logistic regression (binary outcome: mild vs. moderate/severe) models and factors that were statistically significant were further analyzed by multivariate analysis.

Results: The response rate was 54%. Response rates were significantly lower in women overall and in men under the age of 50. Covariates that were significantly associated with more severe self-reported severity of gout in the bivariate logistic

regression models (Table 1) were: female sex, hyperlipidemia, higher number of previous attacks, attack during last month, HAQ. In the multivariate analysis objective measures of gout severity such as more than ten previous attacks and attack during last month were strongly associated with the patients grading of severity, in addition to presence of hyperlipidemia (Table 1).

Table 1. Characteristics of gout patients stratified by disease severity and logistic regression models

Covariates	Mild* n=272	Moderate* n=130	Severe* n=62	Univariate analyses** OR (95% CI)#	Multivariate analyses (OR (95% CI)#
Age in years (mean)	70.8	71.9	71.8	1.01 (0.99–1.02)	N/A
Female sex (%)	12.9	18.5	22.6	1.67 (1.01–2.76)	1.54 (0.85–2.80)
Education ≤9 years (%)	24.8	27.6	46.6	1.46 (0.97–2.21)	N/A
Diabetes (%)	22.8	27.1	27.4	1.29 (0.84–1.98)	N/A
Kidney disease (%)	6.6	9.3	11.3	1.59 (0.81–3.12)	N/A
BMI (mean)	27.9	28.2	27.8	1.02 (0.97–1.06)	N/A
Hyperlipidemia (%)	29.4	44.2	46.8	2.00 (1.36–2.95)	2.13 (1.39–3.28)
Duration of gout in years (mean)	10.4	11.2	8.5	1.00 (0.98–1.01)	N/A
Total number of attacks (%):					
1	19.5	6.4	12.1	ref	ref
2–5	50.0	40.8	39.7	1.93 (1.01–3.67)	1.51 (0.77–2.96)
6–10	14.8	20.8	13.8	2.98 (1.42–6.25)	2.12 (0.97–4.62)
>10	15.6	32.0	34.5	5.00 (2.48–10.09)	3.15 (1.49–6.65)
Attack during the last month (%)	11.5	30.4	30.6	3.43 (2.10–5.61)	1.81 (1.36–2.41)
ULT† (%)	46.3	50.8	50.0	0.85 (0.46–1.55)	N/A
HAQ§ (mean)	0.24	0.29	0.51	1.56 (1.09–2.24)	1.20 (0.80–1.81)
Tophus (%)	14.3	21.3	4.8	1.17 (0.69–1.98)	N/A

*Self-reported disease severity. **ORs reflects yes vs no for dichotomous covariates, per year for age and duration and per unit for HAQ. #Moderate/severe vs mild, †Urate-lowering therapy. § Health assessment questionnaire.

Conclusions: Over 40% of patients with gout in a primary care setting rated their disease as moderate or severe. The validity of the patients rating was supported by other covariates reflecting disease severity. The observations that women and those with hyperlipidemia reported a more severe disease needs to be further explored.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.3452

THU0405 KILLING TWO BIRDS WITH ONE STONE? THE DASH DIET AND THE RISK OF GOUT: 26-YEAR FOLLOW-UP OF A PROSPECTIVE COHORT

S.K. Rai¹, T.T. Fung^{2,3}, N. Lu¹, S.F. Keller¹, G.C. Curhan^{4,5}, H.K. Choi^{1,4}.
¹Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital; ²Department of Nutrition, Harvard T.H. Chan School of Public Health; ³Department of Nutrition, Simmons College; ⁴Channing Division of Network Medicine, Department of Medicine; ⁵Renal Division, Department of Medicine, Brigham and Women's Hospital, Boston, United States

Background: The Dietary Approaches to Stop Hypertension (DASH) diet, which reduces blood pressure and is recommended in cardiovascular disease (CVD) (1,2), has also been found to lower serum uric acid (SUA) levels, particularly among those with hyperuricemia (3). Thus, the DASH diet may be particularly useful in gout care by reducing both SUA and CVD risk, especially among patients with hypertension which affects 74% of gout patients (4), thereby “killing two birds with one stone”. However, corresponding data for the risk of gout are not available. In contrast, a Western dietary pattern may increase the risk of gout.

Objectives: To prospectively examine the relation between the DASH and Western dietary patterns and the risk of gout among men.

Methods: Using the Health Professionals Follow-up Study, we prospectively examined the relation between the DASH and Western diets and incident gout in 44,444 male participants with no history of gout at baseline. Using validated food frequency questionnaires, each participant was assigned a DASH score (reflecting high intake of fruits, vegetables, nuts and legumes, low-fat dairy products, and whole grains, and low intake of sodium, sweetened beverages, and red and processed meats) and a Western pattern score (reflecting higher intake of red and processed meats, French fries, refined grains, sweets, and desserts). We identified incident cases of gout meeting the preliminary ACR survey criteria for gout, adjusting for potential confounders including age, total energy intake, body mass index (BMI), diuretic use, history of hypertension, history of renal failure, and intake of alcohol and coffee. We conducted stratified analyses to evaluate whether the association between the DASH and Western pattern scores and the risk of gout varied according to BMI, alcohol use, and hypertension status.

Results: During 26 years of follow-up, we documented 1,731 confirmed cases of incident gout. A higher DASH score was associated with a lower risk for gout (multivariable relative risk [RR] for extreme quintiles, 0.68 [95% confidence interval, 0.57 to 0.80]; P for trend <0.001) (Table 1). In contrast, a higher Western pattern score was associated with an increased risk for gout (multivariable RR for extreme quintiles, 1.42 [95% confidence interval, 1.16 to 1.74]; P for trend=0.005) (Table 1). These associations persisted regardless of BMI, alcohol use, and hypertension status, and there was no significant interaction with these variables (all P for interaction >0.17).

Table 1. Relative Risk of Incident Gout According to Quintiles of DASH and Western Dietary Pattern Scores

Variable	Frequency of Intake (servings/d)					P for trend
	Q1	Q2	Q3	Q4	Q5	
DASH Diet						
Cases/PY	396/192891	391/195870	366/196511	332/192697	246/193455	
Age-adjusted RR (95% CI)	1.0	0.96 (0.83,1.10)	0.88 (0.77,1.02)	0.81 (0.70,0.94)	0.60 (0.51,0.70)	<0.001
Multivariable RR (95% CI)	1.0	0.90 (0.79,1.04)	0.87 (0.76,1.01)	0.82 (0.70,0.95)	0.68 (0.57,0.80)	<0.001
Western Diet						
Cases/PY	267/190572	347/194533	365/196671	346/197114	386/193182	
Age-adjusted RR (95% CI)	1.0	1.19 (1.02,1.39)	1.25 (1.07,1.46)	1.18 (1.01,1.38)	1.35 (1.16,1.57)	<0.001
Multivariable RR (95% CI)	1.0	1.09 (0.93,1.28)	1.15 (0.98,1.36)	1.12 (0.94,1.33)	1.42 (1.16,1.74)	0.005

Abbreviations: RR, relative risk; CI, confidence interval; PY, person-years.
Age-adjusted models adjusted for age and total energy intake.

Conclusions: The DASH dietary pattern is associated with a lower risk of gout, suggesting that its urate-lowering effect among hyperuricemic individuals translates to a lower risk of gout. Conversely, the Western dietary pattern is associated with a higher risk of gout. The DASH diet may provide an attractive preventive dietary approach for the risk of gout, particularly given the high level of cardiovascular comorbidities among this patient population.

References:

- [1] N Engl J Med. 1997;336(16):1117–24.
- [2] N Engl J Med. 2010;362(22):2102–12.
- [3] Arthritis Rheumatol. 2016;68(12):3002–3009.
- [4] Am J Med. 2012;125(7):679–687.

Acknowledgements: This research was supported by NIH grant R01AR065944.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.3925

THU0406 SERUM URIC ACID LOWERING TREATMENT APPEARS UNNECESSARY DURING HEMODIALYSIS

M. Andrés^{1,2}, R. Soriano¹, E. Oliveira³, C. Trigo³, M.D. Arenas⁴, E. Pascual^{2,5}.
¹Departamento de Medicina Clínica, Universidad Miguel Hernández; ²Sección de Reumatología; ³Servicio de Análisis Clínicos, Hospital General Universitario de Alicante; ⁴Unidad de Nefrología, Hospital Vithas Perpetuo Socorro; ⁵Emeritus Professor, Universidad Miguel Hernández, Alicante, Spain

Background: Gout patients often suffer from renal disease, some ultimately developing end-stage renal disease (ESRD) and requiring hemodialysis (HD) replacement therapy. Though some reports suggested that tophi disappear after HD, urate-lowering agents are frequently continued, often based on persistent high SUA levels before HD. Also, the impact of SUA levels in the survival of patients on hemodialysis (HD) is under discussion.

Objectives: To assess the SUA reduction achieved under HD and analyze the kinetics of SUA in a week of intermittent HD.

Methods: SUA levels were determined before and after HD sessions in consecutive 96 patients with end-stage renal disease (ESRD), and compared through paired samples Student's t test. Variables related to HD were analyzed whether associated with SUA reductions $\geq 80\%$ using Student's t test or ANOVA. Also, a kinetics study on selected 10 patients with hyperuricemia (SUA before HD > 6.8 mg/dL) throughout intermittent HD sessions in a week period was performed; differences in SUA levels were analyzed by repeated measures ANOVA.

Results: Patients were mean aged 66.5 years (SD ± 13.8), 62 males (64.6%). Mean time on HD replacement was 7.1 years (± 7.2). Before starting HD, 43.0% had hyperuricemia and 21.6% reported gout. Sixteen (16.4%) continued on urate-lowering agents after HD. Mean SUA levels before and after HD session was 5.2mg/dL (± 1.0) and 1.0mg/dL (± 0.4), respectively. Mean SUA reduction following HD was 80.2% (95% CI 78.4–82.0); 51 patients (56.7%) showed SUA reduction $\geq 80\%$. HD-related variables Kt/v < 1.3 ($p=0.006$) and blood efflux < 400 mL/min ($p=0.004$) significantly associated with achieving SUA reduction $\geq 80\%$. Figure shows the SUA kinetics study: SUA significantly reduced all over the period and persisted below hyperuricemia threshold ($p=0.015$).

Conclusions: Under HD replacement therapy SUA levels effectively reduced and persisted below saturation point, suggesting that urate-lowering therapy appears unnecessary for patients with gout and ESRD.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.2392

THU0407 HIGH GOUT CLASSIFICATION SCORE IS ASSOCIATED WITH ULTRASOUND FINDINGS IN PATIENTS WITH CRYSTAL-PROVEN GOUT

T. Uhlig, L.F. Karoliussen, E.A. Haavardsholm, T.K. Kvien, H.B. Hammer.
Rheumatology, Diakonhjemmet Hospital, Oslo, Norway

Background: The recent ACR/EULAR classification (1) classify gout in patients with at least 8 out of maximum 23 points, but presence of monosodium urate crystals in a symptomatic joint/tophus alone is sufficient for gout classification without need for further scoring. It is not known how in crystal-proven patients with increased serum urate (sUA) the whole range of classification points distribute.

Objectives: To determine the distribution along the spectrum of ACR/EULAR criteria in crystal-proven patients with insufficiently treated sUA levels, and if disease factors in gout are associated with high classification scores.

Methods: Baseline data from a prospective observational study were used from patients with crystal-proven gout who presented after a recent gout flare. Included patients had at baseline insufficiently treated sUA level (> 360 μ mol/L [> 6 mg/dL]). Demographic, clinical data and sUA levels were collected from September 2015 to December 2016 in one rheumatology department. Ultrasound of joints was assessed with one total score for double contour sign, tophus, and aggregates in several joints and tendons/entheses. The score for ACR/EULAR criteria for gout was calculated.

Results: 89 patients were included, with baseline mean (SD) age 56.0 (14.8) years, 92% males, 88% Caucasians, disease duration 7.9 (7.3) years, presence of palpable tophi 19%, ultrasound score 19.9 (13.8), serum urate 486 (90) μ mol/L, creatinine 78 (18) mL/min, creatinine clearance 78 (18) mL/min, ESR 14 (14) mm/h, body mass index 29.4 (4.9) kg/m², comorbidity score [SCQ] 3.5 (3.2), and physical function [HAQ] 0.34 (0.51). All patients satisfied clearly the scoring arm of the classification criteria with a median (range) 19 (11 – 23) of 23 possible points (Figure 1). Patients with a median and higher score above the median (≥ 19 points) vs. lower score reported more gout flares during the last 12 months ($p<0.001$), had longer disease duration (9.2 vs. 6.2 yrs, $p=0.05$), and a higher ultrasound score (23.9 vs. 14.9, $p=0.001$). The groups with high and low scores were similar for age, gender, ethnicity, level of education, BMI, physical function, comorbidity score, sUA level and kidney function.

Conclusions: As expected, patients seen in the clinic with crystal-proven gout and at least slightly increased sUA also satisfy the scoring arm of the new classification criteria for gout, supporting their clinical use. Patients with classification points above the median had more flares in the preceding year, and a higher urate burden assessed by ultrasound, but did not have other indicators for a more severe disease.

References:

- [1] Neogi T et al. Ann Rheum Dis 2015;74:1789–98.

Disclosure of Interest: T. Uhlig: None declared, L. F. Karoliussen: None declared, E. A. Haavardsholm: None declared, T. K. Kvien Consultant for: Fees for speaking and/or consulting from AbbVie, Biogen, BMS, Boehringer Ingelheim, Celltrion, Eli Lilly, Epirus, Janssen, Merck-Serono, MSD, Mundipharma, Novartis, Oktal, Orion Pharma, Hospira/Pfizer, Roche, Sandoz and UCB, H. B. Hammer: None declared

DOI: 10.1136/annrheumdis-2017-eular.2196

THU0408 GOUT IS AN IMPORTANT PREDICTOR OF WORK DISABILITY IN BOTH MEN AND WOMEN

V. Sigurdardottir^{1,2}, P. Drivelegka¹, A. Svärd², L.T. Jacobsson¹, M. Dehlin¹.

¹Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg; ²Centre for Clinical Research Dalarna, Falun, Sweden

Background: Gout is the most common form of inflammatory arthritis with a prevalence of 1.5% in our area in the age group 50–59 years (1). Gout has a